Sage Journals: Discover world-class research

Abstract

Superficial rhabdomyosarcomas (RMS) represent a rare and diagnostically challenging group of malignant neoplasms that may arise in, involve, or metastasize to the skin. Although RMS is the most common soft tissue sarcoma of childhood, cutaneous and superficial presentations are uncommon and encompass a heterogeneous spectrum of clinicopathologic scenarios. These include primary cutaneous RMS of conventional subtypes, newly recognized molecularly defined entities such as TFCP2-rearranged RMS, rhabdomyosarcomatous transdifferentiation of primary cutaneous malignancies, and metastatic RMS to the skin. Each of these entities may closely mimic a variety of benign and malignant cutaneous tumors, leading to potential diagnostic pitfalls. This review provides a comprehensive overview of superficial RMS, with emphasis on histopathologic features, immunophenotypic profiles, molecular alterations, and key differential diagnoses relevant to dermatopathologists and surgical pathologists. Conventional primary cutaneous RMS subtypes—including alveolar, embryonal, pleomorphic, and spindle cell/sclerosing variants—are discussed alongside emerging entities such as FUS/EWSR1::TFCP2-rearranged RMS, which frequently demonstrate epithelial marker expression and ALK overexpression. In addition, rhabdomyosarcomatous transdifferentiation of melanoma and squamous cell carcinoma is reviewed, highlighting the importance of clinicopathologic correlation and molecular testing to avoid misclassification. Cutaneous metastases of RMS, though exceedingly rare, are also addressed. Recognition of these diverse presentations requires integration of morphologic assessment, immunohistochemistry, and increasingly, molecular diagnostics. Continued clinicopathologic studies and molecular characterization will be essential to refine classification, improve diagnostic accuracy and enhance understanding of the biologic behavior of superficial RMS.

Keywords

rhabdomyosarcoma cutaneous mesenchymal tumor transdifferentiated melanoma transdifferentiated squamous cell carcinoma TFCP2

Introduction

Rhabdomyosarcoma (RMS) is a malignant mesenchymal neoplasm characterized by a skeletal muscle phenotype. It represents the most common soft tissue sarcoma in individuals under the age of 20 and thereby accounts for up to 3% of pediatric cancers.^1–3 Its prognosis is highly variable depending on many factors including patient demographics, tumor site, likelihood of successful resection, and extent of disease.^2,4 While RMS most often arises in the head and neck (∼40%), other common sites include the genitourinary system, extremities, orbit, thorax, and trunk.^5–8 Currently, there are 4 main RMS subtypes recognized by the fifth edition (2020) of the World Health Organization including embryonal RMS, alveolar RMS, spindle cell/sclerosing RMS, and pleomorphic RMS; however, the classification of RMS is rapidly evolving with additional subtypes undergoing active investigations.⁹

Superficial RMSs are rare, and the most common variants include cutaneous involvement of one of the recognized RMS subtypes (listed above), primary cutaneous RMS, transdifferentiation of a primary cutaneous tumor to RMS, metastatic RMS to the skin, and only very rare other scenarios. This article aims to provide a comprehensive review of superficial RMSs, focusing on diagnostic considerations relevant to pathologists, and to encourage further research into their clinical and molecular characterization.

Primary Cutaneous RMS of Conventional Subtypes

Primary cutaneous RMS is rare with only a few case reports and small case series reported in the literature.^3,8,10–16 Most tumors are of alveolar type with exceptionally rare lesions of embryonal and pleomorphic types.^3,8,10–16 While primary cutaneous RMS are rare, involvement of skin from a deep RMS through direct extension is more common.^10,12,15

Clinical Features

Primary cutaneous RMS have been reported in patients of various ages with a possible predilection for men.^10,14 These tumors typically arise in sun-exposed skin of the face and scalp, however reports of tumors arising in the skin of the extremities, chest, anogenital region, and shoulder exist.^10,12 Notably, involvement of the head and neck is most consistently seen in pediatric patients, while the tumors reported in the adult population have a highly variable site distribution.^3,8,10,13,14 Clinically, these tumors vary in presentation and are rather indistinctive, ranging from a benign-appearing erythematous nodule to an indurated plaque.^3,8,10–15 Congenital primary cutaneous RMS in neonates have been reported and are considered aggressive with only few reports of long-term survival.¹³ Notably, primary cutaneous RMS may be misdiagnosed as a benign entity, both clinically or histologically, but often rapidly progress in size and/or metastasize prompting further evaluation.^10,14 Treatment typically consists of resection with adjuvant chemotherapy and/or radiotherapy.^10,11,15 Prognosis is poor, especially in patients where there is delayed treatment due to initial misdiagnosis, with several reports of local recurrence, aggressive metastatic disease, and death despite resection and adjuvant therapy.^10,14

Alveolar Primary Cutaneous RMS

Alveolar RMS comprises approximately 20% to 30% of RMSs and typically affects adolescents and young adults.^17–19 It has a poorer prognosis than embryonal RMS, with lower survival rates and a higher likelihood of metastasis at diagnosis.^9,17 Alveolar primary cutaneous RMS is the most common type of primary cutaneous RMS and has been reported in a variety of age groups with primary sites including the extremities and the head and neck.^3,10–15

Histopathologic and Immunohistochemical Features

Alveolar primary cutaneous RMS histologically consists of a proliferation of round-to-polygonal shaped atypical cells arising from the dermis or subcutis with abundant eosinophilic cytoplasm and eccentrically located hyperchromatic nuclei.^3,10–15 Characteristically, the lesional cells are often arranged in nests or sheets with thick fibrovascular septa and with central loss of cellular cohesion creating the alveolar-like appearance (see Figure 1A-C).¹⁴ High mitotic activity, focal necrosis, and wreath-like giant cells are often seen.^3,10–15 In addition, a second population of atypical spindle cells may be observed.^10,11,14 In most tumors, lesional cells demonstrate a myogenic immunophenotype with strong and diffuse immunohistochemical reactivity with desmin, MYOD1, and importantly myogenin, a notable differentiating attribute from embryonal primary cutaneous RMS (see Figure 1D and E).^3,10–15 S100 expression in the epithelioid or spindle cell component has been seen in a few tumors and one reported tumor expressed neuron-specific enolase.^10,13,15 These tumors are negative for smooth muscle actin, keratins, EMA, HMB-45, and melan-A.^10–12,15

Figure 1.

Histologic and immunohistochemical features of primary cutaneous rhabdomyosarcoma of select conventional subtypes. (A-E) Primary cutaneous alveolar rhabdomyosarcoma involving the dermis (A), composed of pleomorphic cells arranged in a characteristic alveolar-like architecture (B and C), with diffuse expression of myogenin (D) and desmin (E). (F-J) Primary cutaneous pleomorphic rhabdomyosarcoma involving the dermis (F), composed of pleomorphic oval cells with focal rhabdoid morphology and adjacent necrosis (G and H). Lesional cells are negative for MYOD1 (I, a nuclear stain) and show patchy expression of myogenin (J).

Molecular Features

Approximately 85% of alveolar RMS harbor a pathogenic PAX3::FOXO1 or, less commonly, PAX7::FOXO1 fusion.^17,20 However, specimens of alveolar primary cutaneous RMS in which no characteristic fusion were identified have been reported.¹⁴

Embryonal Primary Cutaneous RMS

Embryonal RMS is the most common RMS subtype in children typically affecting those under 5 years old with a predominance in male patients.^20–22 It usually arises in the head and neck region or genitourinary tract and has a relatively favorable prognosis, with a 5-year survival rate of 70% to 85%.^21–23 Embryonal RMS includes 3 main morphologic variants: classic, botryoid, and spindle cell.^20,24 Embryonal primary cutaneous RMS has been predominately reported in the pediatric population and almost exclusively in the head and neck region.^8,10,14

Histopathologic and Immunohistochemical Features

Embryonal primary cutaneous RMS typically consists of primitive appearing ovoid-to-spindled cells with hyperchromatic nuclei, inconspicuous nucleoli, and indistinct cytoplasm.^10,14 Notably, there are often alternating areas of hypercellularity and loose myxoid stroma which leads to a distinctive impression on low power examination.^8,10,14,25 Occasionally, more conspicuous rhabdomyoblastic differentiation can be observed in rare cells as evidenced by abundant eosinophilic cytoplasm and rarely, even cross striations may be visible. By immunohistochemistry, myogenic markers such as Myo-D1, myogenin, and desmin are positive but often more focal and less diffuse than alveolar primary cutaneous RMS, in particular the myogenin expression.^{8,10,12,14,25}

Molecular Features

Molecular analysis of embryonal primary cutaneous RMS has not identified a fusion or genetic hallmark, but the lack of FOXO1-related fusions and/or the presence of mutations in RAS, TP53, or BCOR may be supportive of embryonal primary cutaneous RMS over other RMS subtypes.^20,24

Pleomorphic Primary Cutaneous RMS

Pleomorphic RMS makes up approximately 10% of RMSs; however, it almost exclusively occurs in adults with a predominance in male patients.^7,22,26 Pleomorphic RMS carries a similar prognosis to alveolar RMS with reports of 5-year survival of around 27% to 50%.^22,27 Only a few patients with pleomorphic primary cutaneous RMS have been reported, most occurring in older adults with sites including the scalp, extremities, cheek, and periorbital region.^14,16 However, these studies did not include next-generation sequencing to assess for melanoma-associated driver mutations, and therefore, the possibility that a proportion of these tumors represent transdifferentiated melanomas with rhabdomyosarcomatous differentiation cannot be excluded. In modern practice, pleomorphic primary cutaneous RMS should therefore be approached as a diagnosis of exclusion. At minimum, essential diagnostic features should be met, including histologic features of pleomorphic cells with eosinophilic cytoplasm and immunoreactivity with desmin and myogenin.⁹ It would be desirable to also have supportive clinical characteristics, such as an adult patient with specific sites as described above. Nevertheless, comprehensive immunohistochemical and molecular analysis remains critical to support or refute the diagnosis.

Histopathologic and Immunohistochemical Features

Pleomorphic primary cutaneous RMS is composed of large, highly pleomorphic, spindled or polygonal and often multinucleated cells arranged in a fascicular, storiform, or varying “pattern-less” architecture.^14,16,28 Rhabdoid features, including abundant eosinophilic cytoplasm, may be seen (see Figure 1F-H).^14,16,28 Lesional cells often demonstrate strong and diffuse expression of desmin; however, other myogenic markers, including Myo-D1 and myogenin, can be focal and weak (see Figure 1I and J).^14,28

Molecular Features

Similar to embryonal primary cutaneous RMS, molecular findings have not been reported in pleomorphic primary cutaneous RMS. However, current knowledge of pleomorphic RMS shows a lack of a genetic hallmark.²⁹

Spindle Cell/Sclerosing Primary Cutaneous RMS

Spindle cell/sclerosing RMS are less common than embryonal RMS and alveolar RMS, constituting up to 10% of RMSs.^22,30,31 These tumors most commonly arise in the paratesticular region, head and neck, extremities, and are rarely found intraosseous.^22,30,32 Characterized by spindled and/or sclerosing morphology, this type of RMS consistently harbors pathogenic MYOD1 (L122R) and/or PIK3CA mutations.^30,31,33 Although spindle cell/sclerosing RMS with VGLL2::NCOA2 fusion and other related fusions characteristic of the congenital/infantile subtype, as well as TFCP2-rearranged RMS, were initially classified within this category, emerging evidence suggests that these entities are more accurately considered distinct subtypes warranting separate consideration.^34–36

Primary Cutaneous RMS with FUS/EWSR1::TFCP2 Fusion

TFCP2-rearranged RMS is a recently described subtype of RMS with a strong preference for osseous sites, particularly the craniofacial bones. However, a subset of these tumors arise in soft tissue including superficial sites such as the skin.^37–41 To date, 6 lesions of cutaneous origin have been reported involving the chest, back, mid-thoracic region, flank, shoulder, and scalp.^37–40 While the clinical presentation varies, tumors were described as a firm erythematous nodule, indurated erythematous plaque, morphea-like lesion, multinodular mass, or an ulcerated mass.^37–41 Similar to those arising in bone, primary cutaneous TFCP2-rearranged RMS tends to arise in middle aged adults with a slight predominance in male patients.^37–40 Limited knowledge of radiographic features for primary cutaneous RMS with TFCP2-related fusions exists; however, the appearance of a multilocular mass with low intensity on T-1 weighted and high intensity on T-2 weighted magnetic resonance imaging has been reported in a single case report.³⁷ Treatment typically consists of surgical resection with adjuvant chemotherapy and/or radiotherapy.^37,39 Prognosis is often poor with reports of high-grade malignant transformation, frequent local recurrence, lymph node involvement, and death of disease.^37–39

Histopathologic and Immunohistochemical Features

Histologic features of this rare tumor are variable; however, the most classic pattern is that of a combination of mixed spindled and epithelioid morphology.^37–40 The epithelioid tumor cells tend to be enlarged, with prominent nucleoli, nuclear pleomorphism, and frequent mitotic figures within a myxoid to collagenous stroma (see Figure 2A-D).^37–40 Multinucleated giant cells and zones of necrosis may be seen.^37–39 These tumors tend to show focal to diffuse expression of skeletal muscle markers, in particular MYOD1, with more limited desmin and rare myogenin expression which led to their classification of RMS.^37–40 Notably, in some reports, MYOD1 was only expressed in the round epithelioid tumor cells and was negative in the spindle cell component.³⁷ Importantly, the lesional cells are also often strongly reactive with epithelial markers (e.g., keratin AE1/AE3 and keratin CAM5.2). Another very useful and potentially therapeutically relevant marker is ALK, as a significant subset of tumors show diffuse ALK expression (see Figure 2E-H).^37–41 One possible explanation for this phenomenon is aberrant ALK activation, which may occur through several mechanisms, including the presence of ALK fusions (in addition to the TFCP2 fusion) or internal genomic deletion, but studies further investigating this finding remain limited.^42,43 Some of the reports also mentioned cytoplasmic CD30 expression, predominantly in the high-grade epithelioid components.^37–40 EMA, CD56, and ERG have shown weak or partial positivity in few tumors.³⁸

Figure 2.

Histologic and immunohistochemical features of primary cutaneous rhabdomyosarcoma with FUS/EWSR1::TFCP2 fusion. Sarcomatoid lesion arising within the dermis (A) composed of mixed epithelioid (B and C) and spindle (D) cell morphology with focal necrosis (B) within a myxoid to collagenous stroma. Lesional cells express ALK (E), keratin AE1/AE3 (F), CD30 (G), and MYOD1 (H). *Photographs (A-H) courtesy of Dr Isidro Machado and Dr Sílvia Bagué from Spain

Molecular Features

Molecular analysis will demonstrate FUS/EWSR1::TFCP2 fusion.³⁸ Reports of recurrent FUS::TFCP2 gene fusions have typically involved exon 6 of FUS and exon 2 of TFCP2, with some lesions also demonstrating reciprocal TFCP2::FUS (exon 1 to exon 7) transcripts.^39–42 Additionally, these tumors frequently show partial amplification of the 5′ ALK region and ALK related fusions.⁴²

Notable Diagnostic Considerations and Pitfalls

Due to the rarity of primary cutaneous RMS with TFCP2-related fusions, these tumors may be misdiagnosed at initial presentation. Additionally, ALK overexpression gives rise to a diagnostic pitfall, inflammatory myofibroblastic tumor.³⁹ In addition to ALK positivity, these tumors sometimes demonstrate CD30 reactivity, particularly within the high grade epithelioid components, which potentially mimics anaplastic large cell lymphoma.^37–39 The invasive nature of this tumor accompanied by strong positivity of lesional cells with certain keratins (ie, keratin AE1/AE3 and keratin CAM5.2) may mimic dermal epithelioid sarcoma or sarcomatoid squamous cell carcinoma (SCC).⁴⁰ Additionally, co-expression of desmin may give rise to a differential of desmoplastic small round cell tumor; however, the expression of myogenic markers refute this diagnosis.³⁹ Malignant triton tumor (MTT) is an important differential to include as it may show rhabdomyoblastic features and can present with a myogenic immunophenotype; however, it lacks TFCP2 related fusions.^44,45 A further discussion of MTT can be seen below under “Additional diagnostic considerations for cutaneous tumors with rhabdomyoblastic differentiation.” While additional diagnostic considerations exist, the key to correctly identifying these tumors is to pursue molecular profiling for fusion analysis.³⁸

Rhabdomyosarcomatous Transdifferentiation of Melanoma and Squamous cell carcinoma

Transdifferentiation is a process by which a population of cells undergo phenotypic transformation to that of a different lineage.⁴⁶ Many tumors, especially in the head and neck, have been reported to demonstrate rhabdomyosarcomatous transdifferentiation including malignant peripheral nerve sheath tumors (MTT), undifferentiated thyroid carcinoma, carcinosarcoma of the salivary gland, teratocarcinosarcoma, malignant teratoma, liposarcoma, and olfactory neuroblastoma.⁴⁷ Additionally, several common malignant tumors of the skin are known to have the potential to develop rhabdomyosarcomatous transdifferentiation, morphologically and immunophenotypically.^46–49

Malignant Melanoma With Rhabdomyosarcomatous Transdifferentiation

Malignant melanoma with genuine rhabdomyosarcomatous differentiation is rare, with fewer than 20 patients reported; however, the true incidence may be higher with our continuously improving understanding of the transdifferentiation capacity of this tumor.^46,49–55

Clinical Features

Primary cutaneous melanoma with rhabdomyosarcomatous transdifferentiation clinically presents in middle aged to older adults with a predominance in male patients (∼2-3:1).^49–55 These tumors occur in areas of high sun exposure (eg, face, scalp, forearm) and often present as a large ulcerated and nodular cutaneous mass, although rhabdomyosarcomatous transdifferentiation has been identified in more “classic” flat pigmented lesions.^{49,51–53,55} Overall reports of prognosis varies, with some studies suggesting a similar prognosis to conventional melanoma while others demonstrating a poor prognosis with more than 50% of patients developing metastatic disease, most commonly to the lungs.^48,49,53,55 Treatment often involves resection with adjuvant chemotherapy, immunotherapy, and/or radiotherapy.^49,53

Histopathologic, Immunohistochemical, and Molecular Features

Microscopically, the diagnosis of melanoma with rhabdomyosarcomatous transdifferentiation can be difficult, as the transdifferentiated component often consists of sheets of epithelioid-to-rhabdoid and/or spindle cells with significant pleomorphism and atypia.^{49,51–53,55} Multinucleated giant cells and cytoplasmic hyaline inclusions are often reported (see Figure 3A and B).^51–53,55 Increased mitotic activity and focal necrosis are common.^51–53 However, a key histologic clue is the presence of adjacent or overlying conventional malignant melanoma.⁴⁹ In situations where the tumor has undergone full transdifferentiation or the conventional component has ulcerated, a thorough clinical history may be helpful. Furthermore, architectural features of malignant melanoma may persist even in the transdifferentiated component, including junctional nests, melanin pigment, and tumor-infiltrating lymphocytes.⁴⁹ In addition to a rhabdoid morphologic appearance, melanoma with true rhabdomyosarcomatous transdifferentiation express myogenic immunohistochemical markers.^49,53 While a mixture of melanocytic and myogenic immunohistochemical expression in tumor cells is often reported,⁵³ occasionally tumors may demonstrate only weak or even absent expression of melanocytic markers, including HMB-45, SOX10, S100 protein, and Melan-A (see Figure 3C-F).^49,50,53,54 In those scenarios molecular testing to assess for tumor mutational burden, melanoma-associated driver mutations such as BRAF, NRAS or NF1, UV signature analysis, and/or methylation testing can be performed.^56–59 Notably, PRAME may be helpful in differentiating transdifferentiated melanoma from a primary cutaneous RMS; however, additional studies are required as the data are limited.^49,60 Reported tumors indicate that pleomorphic RMS and embryonal RMS may show diffuse PRAME expression, whereas alveolar RMS have generally been PRAME negative.⁶⁰ Given that most reported lesions of primary cutaneous RMS to date are of the alveolar subtype, this may be useful as a screening tool. However, PRAME expression should not be used in isolation; confirmatory molecular testing is necessary to establish the diagnosis in this context. Future studies evaluating PRAME expression in embryonal RMS and pleomorphic RMS proven to lack melanoma-associated driver mutations, thereby excluding transdifferentiated melanomas, are warranted.

Figure 3.

Histologic and immunohistochemical features of malignant melanoma with rhabdomyosarcomatous transdifferentiation. Sheets of pleomorphic cells with epithelioid and rhabdoid morphology (A and B) including multinucleated cells (B). Lesional cells may retain expression of melanoma markers such as SOX10 (C and D) however areas of partial to complete loss of expression can be observed (C). Characteristically, the lesional cells express myogenic markers such as desmin (E) and MYOD1 (F).

Cutaneous SCC With Rhabdomyosarcomatous Transdifferentiation

Rhabdomyosarcomatous transdifferentiation in SCC is rare with most tumors arising in the head and neck.^47,61–63 Squamous cell carcinoma with spindle cell features, often called sarcomatoid carcinoma, are known to demonstrate morphologic and immunophenotypic transdifferentiation of a variety of lineages including cartilage, bone, and skeletal muscle.⁴⁷ Notably, some reports of cutaneous SCC with morphologic rhabdoid differentiation exist.^64–66 However, given their lack of myogenic marker expression, these seem to represent morphologic mimics rather than representing a tumor of true skeletal muscle phenotype.

Clinical Features

Squamous cell carcinoma of the head and neck with rhabdomyosarcomatous differentiation is rare, associated with tobacco and alcohol use, and typically occurs in older adults.^47,61,62 These tumors often present as a large, exophytic, ulcerated, polypoid mass arising from a mucosal site.⁶² Little is currently known regarding prognostic associations with this observation.

Histopathologic and Immunohistochemical Features

On microscopic examination, rhabdomyosarcomatous transdifferentiation in SCC manifests as a population of pleomorphic polygonal or spindle cells with eosinophilic cytoplasm and an enlarged, eccentrically located hyperchromatic nucleus (see Figure 4A and B).^47,61–63 Additionally, scattered bizarre giant cells may be seen and the presence of longitudinal and transverse striations have been reported.^62,63 Focal necrosis may be seen.⁶² As with melanomas, a key diagnostic clue in recognizing SCC with rhabdomyosarcomatous transdifferentiation is identifying an overlying SCC in-situ component or well-differentiated SCC adjacent to the sarcomatoid component.^47,61–63 However, the in-situ or squamous component may be lost secondary to erosion or obliterated by the sarcomatoid tumor.⁶² Immunohistochemistry can be utilized to highlight the rhabdomyosarcomatous features of these tumors as they often demonstrate strong and diffuse expression of vimentin and myogenic markers.^47,61–63 Importantly, the rhabdomyosarcomatous component may retain focal or weak expression of p40, p63, and keratin (see Figure 4C-E).⁶²

Figure 4.

Histologic and immunohistochemical features of squamous cell carcinoma with rhabdomyosarcomatous transdifferentiation. Sheets of pleomorphic cells with rhabdoid morphology (A and B). Lesional cells show expression of epithelial markers such as keratins (C), along with aberrant expression of myogenic markers including desmin (D) and MYOD1 (E).

Metastatic RMS to a Cutaneous Site

RMSs most commonly metastasize to the regional lymph nodes and lung.⁶⁷ Alveolar RMS has additional reported metastatic sites including the brain, liver, bone, pancreas, breast, kidney, and heart.^5,68,69 Spindle cell/sclerosing RMS shares similar metastatic sites.⁷⁰ However, embryonal RMS has also been reported to metastasize to soft tissues and bone marrow. Pleomorphic RMS has a very high propensity to metastasize to the lungs.⁷¹ Rhabdomyosarcomas metastasizing to a cutaneous site is extremely rare and is more common in pediatric patients compared to adults.⁷² Alveolar RMS is the most common subtype of RMS to metastasize to skin.^73–76

Clinical Features

The clinical presentation of cutaneous metastasis of RMS varies and includes painless pruritic skin lesions, a single nodular fleshy cutaneous mass, “blueberry muffin” rash, and single or multiple tender firm erythematous nodules.^72–78 Cutaneous metastasis most often occurs in pediatric patients.⁷² Time to presentation of skin metastasis after initial diagnosis of RMS varies and has not been definitely studied, however based on existing case reports it ranges from 3 months to several years.^72–78 Prognosis is poor with a 5-year survival of 20% to 30% reported in patients with metastatic RMS.⁷⁹

Histopathologic and Immunohistochemical Features

The histologic features of metastatic RMS to a cutaneous site include infiltrative nests and sheets of pleomorphic small round blue cells often involving both the dermis and subcutis.^72–78 High mitotic activity is often seen.^72,74–78 The tumor often exhibits the architectural pattern associated with the primary RMS subtype, such as embryonal (eg, myxoid stroma) and alveolar (eg, nested growth with fibrous septa) (see Figure 5A-D).^72–78 Immunohistochemical studies aid in confirming the diagnosis, with expression of myogenic markers including desmin, muscle-specific actin reactivity, myogenin, and MYOD1.^72–78 Keratin and leukocyte common antigen negativity may aid in excluding more common metastatic neoplasms of the skin (see Figure 5E-H). Notably, N-MYC amplification, with up to a 100-fold increase in copy number, has been reported in a neonate with metastatic alveolar RMS to the skin.¹⁰

Figure 5.

Histologic and immunohistochemical features of metastatic alveolar rhabdomyosarcoma to a cutaneous site. Infiltrative sheets of pleomorphic blue cells involving the dermis (A) with characteristic fibrous septa and central loss of cellular cohesion creating the alveolar-like pattern (B and C). Lesional cells exhibit focal rhabdoid morphology, including eccentrically located nuclei and abundant eosinophilic cytoplasm (D), and express myogenic markers including desmin (E), MYOD1 (F), and myogenin (G), while lacking keratin expression (H).

Additional Diagnostic Considerations for Cutaneous Tumors with Rhabdomyoblastic Differentiation

There is a broad differential for a cutaneous tumor with rhabdomyoblastic differentiation, including many of the entities already discussed in this review. Malignant triton tumor (MTT), which is a rare subtype of malignant peripheral nerve sheath tumor with rhabdomyoblastic differentiation, is a key or potentially challenging differential to include especially in the context of primary cutaneous RMS, cutaneous metastasis of RMS, or prototypical cutaneous neoplasms with rhabdomyoblastic differentiation (eg, SCC and melanoma).^10,13,15,80 MTT often demonstrate a biphasic histologic appearance, including a spindle cell component and a rhabdomyoblastic component.^44,80 Additionally, MTT often express myogenic markers, making it a challenging differential to exclude.^44,80 However, MTTs often additionally show focal SOX10 expression, a marker not described in primary cutaneous RMS.^45,80 MTTs typically arise in deep soft tissues, may be associated with neurofibromatosis type I, and often lose H3K27me3, which, according to current literature, is retained in primary cutaneous RMS.^44,81 Additionally, molecular testing can be helpful as MTTs usually show loss of NF1, CDKN2A/B deletions, and mutations involving EED or SUZ12.¹¹An additional entity which shows focal but consistent rhabdomyoblastic differentiation is the recently characterized sarcoma harboring a EWSR1::PATZ1 fusion.⁸² These tumors often express myogenic, in addition to neural and epithelial immunohistochemical markers.^83,84 Notably, PATZ1-related sarcomas have been reported in the central nervous system, lungs, chest wall, axilla, and head and neck; with no definitive reports of tumors arising as a primary cutaneous lesion.⁸² However, the immunophenotype is a potential mimic of RMS and should be brought into the differential especially in patients where the mass may be arising from deep soft tissues and involving the skin.^82–84

Conclusion

Superficial RMS, including primary cutaneous RMS, rhabdomyosarcomatous transdifferentiation of a “traditional” cutaneous neoplasm, and metastases, represent a rare and diagnostically challenging group of neoplasms that may mimic a range of primary and metastatic tumors. Recognition of histologic patterns, immunophenotypic profiles, and molecular alterations is essential for accurate diagnosis and appropriate classification. Further investigation and case reporting will be critical to elucidate the clinicopathologic spectrum of these tumors.

Footnotes

ORCID iD

Carina A. Dehner

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

Sankhe

Hall

Kendall

. Fusion oncogenes in rhabdomyosarcoma: model systems, mechanisms of tumorigenesis, and therapeutic implications. Front Oncol. 2025;15:1570070. doi:10.3389/fonc.2025.1570070

Ognjanovic

Linabery

Charbonneau

Ross

. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer. 2009;115(18):4218‐4226. doi:10.1002/cncr.24465

Chang

Dehner

Egbert

. Primary cutaneous rhabdomyosarcoma. Am J Surg Pathol. 1990;14(10):977‐982. doi:10.1097/00000478-199010000-00012

McEvoy

Siegel

Dai

, et al. Pediatric rhabdomyosarcoma incidence and survival in the United States: an assessment of 5656 cases, 2001-2017. Cancer Med. 2023;12(3):3644‐3656. doi:10.1002/cam4.5211

Enzinger

Shiraki

. Alveolar rhabdomyosarcoma. An analysis of 110 cases. Cancer. 1969;24(1):18‐31. doi:10.1002/1097-0142(196907)24:1 < 18::AID-CNCR2820240103 > 3.0.CO;2-5

Leiner

Le Loarer

The current landscape of rhabdomyosarcomas: an update. Virchows Arch. 2020;476(1):97‐108. doi:10.1007/s00428-019-02676-9

Agaram

. Evolving classification of rhabdomyosarcoma. Histopathology. 2022;80(1):98‐108. doi:10.1111/his.14449

Tari

Amoli

Rajabi

Esfahani

Rahimi

. Cutaneous embryonal rhabdomyosarcoma presenting as a nodule on cheek; a case report and review of literature. Orbit. 2006;25(3):235‐238. doi:10.1080/01676830600575535

WHO Classification of Tumours Editorial Board. World Health Organization Classification of Tumours of Soft Tissue and Bone. 5th ed. International Agency for Research on Cancer Press; 2020.

10.

Schmidt

Fletcher

Harms

. Rhabdomyosarcomas with primary presentation in the skin. Pathol Res Pract. 1993;189(4):422‐427. doi:10.1016/S0344-0338(11)80330-4

11.

Setterfield

Sciot

Debiec-Rychter

Robson

Calonje

. Primary cutaneous epidermotropic alveolar rhabdomyosarcoma with t(2;13) in an elderly woman: case report and review of the literature. Am J Surg Pathol. 2002;26(7):938‐944. doi:10.1097/01.PAS.0000018105.32686.1F

12.

Binesh

Ardakani

Kamal

Pourhosseini

Mirhosseini

Shahcheraghi

. Primary cutaneous alveolar rhabdomyosarcoma, an uncommon entity. Med J DY Patil Vidyapeeth. 2021;14(6):709‐711. doi:10.4103/mjdrdypu.mjdrdypu_337_20

13.

Brecher

Reyes-Mugica

Kamino

Chang

. Congenital primary cutaneous rhabdomyosarcoma in a neonate. Pediatr Dermatol. 2003;20(4):335‐338. doi:10.1046/j.1525-1470.2003.20413.x

14.

Marburger

Gardner

Prieto

Billings

. Primary cutaneous rhabdomyosarcoma: a clinicopathologic review of 11 cases. J Cutan Pathol. 2012;39(11):987‐995. doi:10.1111/cup.12007

15.

Wong

Suster

. Primary cutaneous sarcomas showing rhabdomyoblastic differentiation. Histopathology. 1995;26(1):25‐32. doi:10.1111/j.1365-2559.1995.tb00616.x

16.

Oliphant

Taylor

Rajak

. Primary cutaneous pleomorphic rhabdomyosarcoma in the periocular region. Clin Exp Ophthalmol. 2019;47(1):140‐141. doi:10.1111/ceo.13141

17.

Wang

. Childhood rhabdomyosarcoma: recent advances and prospective views. J Dent Res. 2012;91(4):341‐350. doi:10.1177/0022034511421490

18.

Perez

Kassira

Cheung

Koniaris

Neville

Sola

. Rhabdomyosarcoma in children: a SEER population based study. J Surg Res. 2011;170(2):e243‐e251. doi:10.1016/j.jss.2011.03.001

19.

Rudzinski

Kelsey

Vokuhl

, et al. Pathology of childhood rhabdomyosarcoma: a consensus opinion document from the Children’s Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. Pediatr Blood Cancer. 2021;68(3):e28798. doi:10.1002/pbc.28798

20.

Dehner

Rudzinski

Davis

. Rhabdomyosarcoma: updates on classification and the necessity of molecular testing beyond immunohistochemistry. Hum Pathol. 2024;147:72‐81. doi:10.1016/j.humpath.2023.12.004

21.

PDQ Pediatric Treatment Editorial Board. Childhood Rhabdomyosarcoma Treatment (PDQ®): Health Professional Version. National Cancer Institute. Updated August 15, 2025. Accessed October 5, 2025.

22.

Amer

Thomson

Congiusta

, et al. Epidemiology, incidence, and survival of rhabdomyosarcoma subtypes: SEER and ICES database analysis. J Orthop Res. 2019;37(10):2226‐2230. doi:10.1002/jor.24387

23.

Wang

Feng

Zhang

Chen

Feng

. Characteristics and prognosis of embryonal rhabdomyosarcoma in children and adolescents: an analysis of 464 cases from the SEER database. Pediatr Investig. 2020;4(4):242‐249. doi:10.1002/ped4.12220

24.

Parham

Barr

. Classification of rhabdomyosarcoma and its molecular basis. Adv Anat Pathol. 2013;20(6):387‐397. doi:10.1097/PAP.0b013e3182a92d0d

25.

Rudzinski

Teot

Anderson

, et al. Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma. Am J Clin Pathol. 2013;140(1):82‐90. doi:10.1309/AJCPA1WN7ARPCMKQ

26.

Noujaim

Thway

Jones

, et al. Adult pleomorphic rhabdomyosarcoma: a multicentre retrospective study. Anticancer Res. 2015;35(11):6213‐6217.

27.

Kobayashi

Okajima

Zhang

, et al. Prognostic factors and treatment outcomes in patients with pleomorphic rhabdomyosarcoma: a population-based cohort study. Jpn J Clin Oncol. 2024;54(4):471‐478. doi:10.1093/jjco/hyad188

28.

Stock

Chibon

Nguyen Binh

, et al. Adult-type rhabdomyosarcoma: analysis of 57 cases with clinicopathologic description, identification of 3 morphologic patterns and prognosis. Am J Surg Pathol. 2009;33(12):1850‐1859. doi:10.1097/PAS.0b013e3181be6209

29.

Fan

Parham

Wang

. An integrative morphologic and molecular approach for diagnosis and subclassification of rhabdomyosarcoma. Arch Pathol Lab Med. 2022;146(8):953‐959. doi:10.5858/arpa.2021-0183-RA

30.

Chen

Rudzinski

Arnold

. Challenges in the diagnosis of pediatric spindle cell/sclerosing rhabdomyosarcoma. Surg Pathol Clin. 2020;13(4):729‐738. doi:10.1016/j.path.2020.08.010

31.

Carroll

Nodit

. Spindle cell rhabdomyosarcoma: a brief diagnostic review and differential diagnosis. Arch Pathol Lab Med. 2013;137(8):1155‐1158. doi:10.5858/arpa.2012-0465-RS

32.

Zhao

Yin

Zhang

, et al. Spindle cell/sclerosing rhabdomyosarcoma: case series from a single institution emphasizing morphology, immunohistochemistry and follow-up. Int J Clin Exp Pathol. 2015;8(11):13814‐13820.

33.

Agaram

LaQuaglia

Alaggio

, et al. MYOD1-mutant Spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification. Mod Pathol. 2019;32(1):27‐36. doi:10.1038/s41379-018-0120-9

34.

Mosquera

Sboner

Zhang

, et al. Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosomes Cancer. 2013;52(6):538‐550. doi:10.1002/gcc.22050

35.

Alaggio

Zhang

Sung

, et al. A molecular study of pediatric spindle and sclerosing rhabdomyosarcoma: identification of novel and recurrent VGLL2-related fusions in infantile cases. Am J Surg Pathol. 2016;40(2):224‐235. doi:10.1097/PAS.0000000000000538

36.

Suurmeijer

AJH

Agaram

Zhang

Antonescu

. Head and neck rhabdomyosarcoma with TFCP2 fusions and ALK overexpression: a clinicopathological and molecular analysis of 11 cases. Histopathology. 2021;79(3):347‐357. doi:10.1111/his.14323

37.

Ishiyama

Kato

Ito

, et al. Rhabdomyosarcoma with FUS::TFCP2 fusion in the scalp: a rare case report depicting round and spindle cell morphology. Int J Surg Pathol. 2023;31(5):805‐812. doi:10.1177/10668969221137517

38.

Machado

Wardelmann

Zhao

, et al. Primary cutaneous rhabdomyosarcoma with EWSR1/FUS::TFCP2 fusion: four new cases with distinctive morphology, immunophenotypic, and genetic profile. Virchows Arch. 2025;486(6):1187‐1198. doi:10.1007/s00428-024-04007-z

39.

Tsuji

Fujimoto

Togashi

, et al. Cutaneous rhabdomyosarcoma with FUS::TFCP2 Fusion: An emerging entity that expands the differential diagnosis of ALK-positive spindle cell neoplasm of the skin. Am J DermatopatholPublished online June 26,2025;47(9):703–708. doi:10.1097/DAD.0000000000003031

40.

Demirkesen

Danyeli

Yıldız

, et al. Cutaneous rhabdomyosarcoma with FUS::TFCP2 fusion: a case report emphasizing early detection. J Cutan Pathol. 2023;50(12):1059‐1064. doi:10.1111/cup.14526

41.

Schöpf

Uhrig

Heilig

, et al. Multi-omic and functional analysis for classification and treatment of sarcomas with FUS-TFCP2 or EWSR1-TFCP2 fusions. Nat Commun. 2024;15(1):51. doi:10.1038/s41467-023-44360-2

42.

Bradová

Mosaieby

Michal

, et al. Spindle cell rhabdomyosarcomas: with TFCP2 rearrangements, and novel EWSR1::ZBTB41 and PLOD2::RBM6 gene fusions. A study of five cases and review of the literature. Histopathology. 2024;84(5):776‐793. doi:10.1111/his.15121

43.

Le Loarer

Cleven

AHG

Bouvier

, et al. A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation. Mod Pathol. 2020;33(3):404‐419. doi:10.1038/s41379-019-0323-8

44.

Ducatman

Scheithauer

. Malignant peripheral nerve sheath tumors with divergent differentiation. Cancer. 1984;54(6):1049‐1057. doi:10.1002/1097-0142(19840915)54:6 < 1049::AID-CNCR2820540620 > 3.0.CO;2-1

45.

Kang

Pekmezci

Folpe

Ersen

Horvai

. Diagnostic utility of SOX10 to distinguish malignant peripheral nerve sheath tumor from synovial sarcoma, including intraneural synovial sarcoma. Mod Pathol. 2014;27(1):55‐61. doi:10.1038/modpathol.2013.115

46.

Wang

Liu

Zhang

, et al. Direct transdifferentiation of tumorigenic melanoma cells induces tumor cell reversion. Cell Death Dis. 2025;16(1):563. doi:10.1038/s41419-025-07863-y

47.

Bishop

Thompson

LDR

Cardesa

, et al. Rhabdomyoblastic differentiation in head and neck malignancies other than rhabdomyosarcoma. Head Neck Pathol. 2015;9(4):507‐518. doi:10.1007/s12105-015-0624-2

48.

Ferreira

Arends

van der Weyden

Adams

Brenn

. Primary de-differentiated, trans-differentiated and undifferentiated melanomas: overview of the clinicopathological, immunohistochemical and molecular spectrum. Histopathology. 2022;80(1):135‐149. doi:10.1111/his.14545

49.

Weigelt

Pattali

Dermawan

Fritchie

Billings

. Primary cutaneous neoplasm with rhabdomyosarcomatous differentiation and a melanoma-like mutational landscape. J Cutan Pathol. 2025;52(6):414‐417. doi:10.1111/cup.14806

50.

Tran

TAN

Linos

de Abreu

Carlson

. Undifferentiated sarcoma as intermediate step in the progression of malignant melanoma to rhabdomyosarcoma: histologic, immunohistochemical, and molecular studies of a new case of malignant melanoma with rhabdomyosarcomatous differentiation. Am J Dermatopathol. 2019;41(3):221‐229. doi:10.1097/DAD.0000000000001236

51.

Kuwadekar

Allard

Dardik

Smith

. Melanoma with rhabdomyosarcomatous differentiation. BMJ Case Rep. 2018;2018. doi:10.1136/bcr-2018-224263

52.

Antonov

Niedt

. Malignant melanoma with rhabdomyosarcomatous differentiation. Am J Dermatopathol. 2016;38(6):456‐460. doi:10.1097/DAD.0000000000000478

53.

Iliesiu

Nimigean

Tapoi

Costache

. Primary cutaneous rhabdomyosarcomatous melanomas—A report of two cases and literature review. Diagnostics. 2025;15(11):1357. doi:10.3390/diagnostics15111357

54.

Dumitru

Tampa

MŞ

Georgescu

, et al. Immunohistochemical mismatch in a case of rhabdomyoblastic metastatic melanoma. Rom J Morphol Embryol. 2018;59(1):339‐344.

55.

Țăpoi

Gheorghișan-Gălățeanu

Dumitru

, et al. Primary undifferentiated/dedifferentiated cutaneous melanomas-A review on histological, immunohistochemical, and molecular features with emphasis on prognosis and treatment. Int J Mol Sci. 2023;24(12). doi:10.3390/ijms24129985

56.

Kasago

Chatila

Lezcano

, et al. Undifferentiated and dedifferentiated metastatic melanomas masquerading as soft tissue sarcomas: mutational signature analysis and immunotherapy response. Mod Pathol. 2023;36(8):100165. doi:10.1016/j.modpat.2023.100165

57.

Agaimy

Specht

Stoehr

, et al. Metastatic malignant melanoma with complete loss of differentiation markers (undifferentiated/dedifferentiated melanoma): analysis of 14 patients emphasizing phenotypic plasticity and the value of molecular testing as surrogate diagnostic marker. Am J Surg Pathol. 2016;40(2):181‐191. doi:10.1097/PAS.0000000000000527

58.

Jackett

Mitchell

Snell

, et al. Molecular analysis of cutaneous sarcomatoid neoplasms frequently identifies melanoma driver variants. Am J Surg Pathol. 2025;49(7):650‐657. doi:10.1097/PAS.0000000000002390

59.

Erdem

Ameline

Bovée

JVMG

, et al. The utility of DNA methylation profiling in the diagnosis of un-, de- and trans-differentiated melanoma: a series of 11 cases. Histopathology. 2025;86(2):247‐259. doi:10.1111/his.15309

60.

Cammareri

Beltzung

Michal

, et al. PRAME immunohistochemistry in soft tissue tumors and mimics: a study of 350 cases highlighting its imperfect specificity but potentially useful diagnostic applications. Virchows Arch. 2023;483(2):145‐156. doi:10.1007/s00428-023-03606-6

61.

Goldman

Weidner

. Pure squamous cell carcinoma of the larynx with cervical nodal metastasis showing rhabdomyosarcomatous differentiation. Am J Surg Pathol. 1993;17(4):415‐421. doi:10.1097/00000478-199304000-00013

62.

Shine

Alvarez Monreno

Coblens

Qiu

Clement

. Laryngeal sarcomatoid carcinoma with rhabdomyoblastic differentiation: a potential pitfall for misdiagnosis as rhabdomyosarcoma. Cureus. 2023;15(6):e40990. doi:10.7759/cureus.40990

63.

Srinivasan

Talvalkar

. True carcinosarcoma of the larynx: a case report. J Laryngol Otol. 1979;93(10):1031‐1035. doi:10.1017/S002221510008806X

64.

Mathers

O’Donnell

. Squamous cell carcinoma of skin with a rhabdoid phenotype: a case report. J Clin Pathol. 2000;53(11):868‐870. doi:10.1136/jcp.53.11.868

65.

Bobkova

Oldham

Gomez-Meade

Shendrik

. Primary cutaneous rhabdoid squamous cell carcinoma: a case report and review of molecular features. Cureus. 2024;16(11):e73592. doi:10.7759/cureus.73592

66.

Pai

. Rhabdoid phenotype in cutaneous squamous carcinoma: an earlier report!. J Clin Pathol. 2001;54(8):656‐656. doi:10.1136/jcp.54.8.656

67.

Nishida

Tsukushi

Urakawa

, et al. High incidence of regional and in-transit lymph node metastasis in patients with alveolar rhabdomyosarcoma. Int J Clin Oncol. 2014;19(3):536‐543. doi:10.1007/s10147-013-0571-4

68.

Vanella

Marengo

Blando

Villa

. Alveolar rhabdomyosarcoma with cardiac metastasis in a pediatric patient. Arch Argent Pediatr. 2021;119(4):349–352. doi:10.5546/aap.2021.e349

69.

Shimada

Newton

Soule

Beltangady

Maurer

. Pathology of fatal rhabdomyosarcoma. Report from intergroup rhabdomyosarcoma study (IRS-I and IRS-II). Cancer. 1987;59(3):459‐465. doi:10.1002/1097-0142(19870201)59:3 < 459::AID-CNCR2820590318 > 3.0.CO;2-K

70.

Rudzinski

Anderson

Hawkins

Skapek

Parham

Teot

. The World Health Organization Classification of skeletal muscle tumors in pediatric rhabdomyosarcoma: a report from the Children’s Oncology Group. Arch Pathol Lab Med. 2015;139(10):1281‐1287. doi:10.5858/arpa.2014-0475-OA

71.

Benkhaled

Mané

Jungels

Shumelinsky

Aubain

Van Gestel

. Successful treatment of synchronous chemoresistant pulmonary metastasis from pleomorphic rhabdomyosarcoma with stereotaxic body radiation therapy: a case report and a review of the literature. Cancer Treat Res Commun. 2021;26:100282. doi:10.1016/j.ctarc.2020.100282

72.

Shimizu

Yasui

Minauchi

Tsuchiya

. Metastatic rhabdomyosarcoma of the skin. J Am Acad Dermatol. 2008;58(5):S118‐S120. doi:10.1016/j.jaad.2007.05.020

73.

Elomrani

Touri

Ouziane

, et al. Orbital rhabdomyosarcoma with skin metastasis: a case report. BMC Res Notes. 2014;7(1):670. doi:10.1186/1756-0500-7-670

74.

Enechukwu

Ifeanyi

Ogun

Ogunbiyi

. Cutaneous metastases of embryonal rhabdomyosarcoma in a black African child: the role of dermoscopy in reducing time to and cost of diagnosis. Ecancermedicalscience. 2021;15:1304. doi:10.3332/ecancer.2021.1304

75.

Nör

Castro

Wongpattaraworakul

, et al. Cutaneous metastasis of alveolar rhabdomyosarcoma in a child. Am J Dermatopathol. 2023;45(3):e17‐e21. doi:10.1097/DAD.0000000000002382

76.

Kim

Jun

Shim

Park

Lee

. Cutaneous metastasis of rhabdomyosarcoma originated from maxillary sinus in a young adult female. Ann Dermatol. 2016;28(4):519‐521. doi:10.5021/ad.2016.28.4.519

77.

Godambe

Rawal

. Blueberry muffin rash as a presentation of alveolar cell rhabdomyosarcoma in a neonate. Acta Paediatr. 2000;89(1):115‐117. doi:10.1080/080352500750029185

78.

Simsir

Ioffe

Henry

. Adult rhabdomyosarcoma with skin metastases: diagnosis by fine needle aspiration biopsy. Acta Cytol. 2001;45(1):106‐108.

79.

Ruymann

Grovas

. Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas. Cancer Invest. 2000;18(3):223‐241. doi:10.3109/07357900009031827

80.

Brooks

JSJ

Freeman

Enterline

. Malignant “triton” tumors. Natural history and immunohistochemistry of nine new cases with literature review. Cancer. 1985;55(11):2543‐2549. doi:10.1002/1097-0142(19850601)55:11 < 2543::AID-CNCR2820551105 > 3.0.CO;2-4

81.

Prieto-Granada

Wiesner

Messina

Jungbluth

Chi

Antonescu

. Loss of H3K27me3 expression is a highly sensitive marker for sporadic and radiation-induced MPNST. Am J Surg Pathol. 2016;40(4):479‐489. doi:10.1097/PAS.0000000000000564

82.

Bridge

Sumegi

Druta

, et al. Clinical, pathological, and genomic features of EWSR1-PATZ1 fusion sarcoma. Mod Pathol. 2019;32(11):1593‐1604. doi:10.1038/s41379-019-0301-1

83.

Michal

Rubin

Agaimy

, et al. EWSR1-PATZ1-rearranged Sarcoma: a report of nine cases of spindle and round cell neoplasms with predilection for thoracoabdominal soft tissues and frequent expression of neural and skeletal muscle markers. Mod Pathol. 2021;34(4):770‐785. doi:10.1038/s41379-020-00684-8

84.

Yau

DTW

Wong

Chow

. Round cell sarcoma with EWSR1-PATZ1 fusion in the face of a five-year-old boy: report of a case with unusual histologic features. Head Neck Pathol. 2021;15(4):1350‐1358. doi:10.1007/s12105-021-01285-w

Superficial Rhabdomyosarcomas: A Review of Subtypes,Diagnostic Features,and Differential Diagnoses

Abstract

Keywords

Introduction

Primary Cutaneous RMS of Conventional Subtypes

Clinical Features

Alveolar Primary Cutaneous RMS

Histopathologic and Immunohistochemical Features

Molecular Features

Embryonal Primary Cutaneous RMS

Histopathologic and Immunohistochemical Features

Molecular Features

Pleomorphic Primary Cutaneous RMS

Histopathologic and Immunohistochemical Features

Molecular Features

Spindle Cell/Sclerosing Primary Cutaneous RMS

Primary Cutaneous RMS with FUS/EWSR1::TFCP2 Fusion

Histopathologic and Immunohistochemical Features

Molecular Features

Notable Diagnostic Considerations and Pitfalls

Rhabdomyosarcomatous Transdifferentiation of Melanoma and Squamous cell carcinoma

Malignant Melanoma With Rhabdomyosarcomatous Transdifferentiation

Clinical Features

Histopathologic, Immunohistochemical, and Molecular Features

Cutaneous SCC With Rhabdomyosarcomatous Transdifferentiation

Clinical Features

Histopathologic and Immunohistochemical Features

Metastatic RMS to a Cutaneous Site

Clinical Features

Histopathologic and Immunohistochemical Features

Additional Diagnostic Considerations for Cutaneous Tumors with Rhabdomyoblastic Differentiation

Conclusion

Footnotes

ORCID iD

Funding

Declaration of Conflicting Interests

References